Category REGENERATIVE MEDICINE

PIER MARIA FORNASARI
2020-02-02

Mayo Clinic CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue–Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury

Stem cells derived from a patient’s own fat offer a step toward improving—not just stabilizing—motor and sensory function of people with spinal cord injuries, according to early research from Mayo Clinic. A clinical trial enrolled 10 adults to treat paralysis from traumatic spinal cord injury. After stem cell injection, the first patient demonstrated improvement in motor

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2020-02-02

HER2-Directed CAR T-Cell Therapy Appears Active in Phase I Trial for Advanced Sarcoma

Source Targeted Oncology Patients with sarcomas, including osteosarcoma in particular, have limited treatment options available, and the landscape has not advanced in over 40 years, according to Shoba A. Navai, MD. However, trials are now evaluating the potential role of chimeric antigen receptor (CAR) T cells as treatment of patients with sarcoma. In a phase

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2020-01-31

UNC Lineberger discovery would allow researchers to fine-tune activity of CAR-T cancer-hunting immune cells

A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects. In a study published in Cancer Cell, researchers led by UNC Lineberger’s Gianpietro Dotti, MD, reported

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2020-01-31

Reducing Hypothalamic Stem Cell Senescence Protects against Aging-Associated Physiological Decline

Source Cell Metabolism Age-dependent loss of hypothalamic neural stem cells (htNSCs) is important for the pathological consequences of aging; however, it is unclear what drives the senescence of htNSCs. Here, it’s reported that a long non-coding RNA, Hnscr, is abundantly expressed in the htNSCs of young mice but decreases markedly in middle-aged mice. Depletion of

Read More

No Comments InAGEING
PIER MARIA FORNASARI
2020-01-30

NUS Medicine researchers can now reprogramme cells to revert to original state for regenerative medicine

Inducing totipotency into stem cells outside of embryos will allow maximal cell engineering for therapeutic purposes Early mammalian development is a highly complex process involving elaborate and highly coordinated biological processes. One such process is zygotic genome activation (ZGA) which occurs following the union of the sperm and egg, marking the beginning of life. The

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2020-01-30

Penn Researchers Identify Cancer Cell Defect Driving Resistance to CAR T Cell Therapy

Study identifying mechanism that prevents cell death may guide future immunotherapy strategies Some cancer cells refuse to die, even in the face of powerful cellular immunotherapies like CAR T cell therapy, and new research from the Abramson Cancer Center of the University of Pennsylvania is shedding light on why. In a new study, researchers describe how a

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2020-01-30

Supporting progress of cell and gene therapy industrialisation with new aseptic manufacturing course

The University of Hertfordshire and the Cell and Gene Therapy Catapult (CGT Catapult) have announced the launch of a new course specifically addressing the foreseeable skills gap in the manufacture of cell and gene therapies as they progress towards manufacturing at scale. Developed in a collaboration between the two organisations, this three-day course will provide

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2020-01-29

New gene correction therapy for Duchenne muscular dystrophy. Gene scissors against incurable muscular disease

Duchenne type muscular dystrophy (DMD) is the most common hereditary muscular disease among children, leaving them wheelchair-bound before the age of twelve and reducing life expectancy. Researchers at Technical University of Munich (TUM), Ludwig Maximilian University of Munich (LMU) and the German Research Center for Environmental Health (Helmholtz Zentrum München) have developed a gene therapy

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2020-01-29

European Medicines Agency Validates Kite’s Marketing Application for Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma

Investigational KTE-X19 To Be First Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma in Europe if Approved Kite, a Gilead Company, today announced that the company’s Marketing Authorization Application (MAA) for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL),

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2020-01-29

EC approves Siponimod for secondary progressive multiple sclerosis

Mayzent (siponimod) has been approved by the European Commission (EC) for adults with secondary progressive multiple sclerosis (SPMS) based on the results of the EXPAND trial. The European Commission (EC) has approved Mayzent (siponimod) for the treatment of adults with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. Approximately 80

Read More

No Comments InEMA